These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28219728)

  • 1. Do cystic fibrosis patients on azithromycin need electrocardiogram monitoring?
    Sharpton R; Condren M; O'Neal K; Lloyd A; McIntosh H
    Pulm Pharmacol Ther; 2017 Apr; 43():55-56. PubMed ID: 28219728
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of azithromycin in patients with cystic fibrosis.
    Yousef AA; Jaffe A
    Paediatr Respir Rev; 2010 Jun; 11(2):108-14. PubMed ID: 20416547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis.
    Florescu DF; Murphy PJ; Kalil AC
    Pulm Pharmacol Ther; 2009 Dec; 22(6):467-72. PubMed ID: 19328860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term azithromycin may improve lung function in children with cystic fibrosis.
    Jaffé A; Francis J; Rosenthal M; Bush A
    Lancet; 1998 Feb; 351(9100):420. PubMed ID: 9482305
    [No Abstract]   [Full Text] [Related]  

  • 5. Azithromycin for cystic fibrosis.
    Southern KW; Barker PM
    Eur Respir J; 2004 Nov; 24(5):834-8. PubMed ID: 15516680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Has the time come to prescribe azithromycin in cystic fibrosis patients?
    McCormack JG; Bell SC
    Intern Med J; 2005 Feb; 35(2):73-4. PubMed ID: 15705133
    [No Abstract]   [Full Text] [Related]  

  • 7. How long should we maintain long-term azithromycin treatment in cystic fibrosis patients?
    Willekens J; Eyns H; Malfroot A
    Pediatr Pulmonol; 2015 Jan; 50(1):103-4. PubMed ID: 24464958
    [No Abstract]   [Full Text] [Related]  

  • 8. Azithromycin, the multidrug-resistant protein, and cystic fibrosis.
    Altschuler EL
    Lancet; 1998 Apr; 351(9111):1286. PubMed ID: 9643772
    [No Abstract]   [Full Text] [Related]  

  • 9. An evaluation strategy for potential QTc prolongation with chronic azithromycin therapy in cystic fibrosis.
    Lenehan PJ; Schramm CM; Collins MS
    J Cyst Fibros; 2016 Mar; 15(2):192-5. PubMed ID: 26698953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa.
    Saiman L; Mayer-Hamblett N; Anstead M; Lands LC; Kloster M; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
    Pediatr Pulmonol; 2012 Jul; 47(7):641-8. PubMed ID: 22684984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients.
    Catherinot E; Roux AL; Vibet MA; Bellis G; Lemonnier L; Le Roux E; Bernède-Bauduin C; Le Bourgeois M; Herrmann JL; Guillemot D; Gaillard JL;
    Eur Respir J; 2013 May; 41(5):1101-6. PubMed ID: 22936714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long-term safety of chronic azithromycin use in adult patients with cystic fibrosis, evaluating biomarkers for renal function, hepatic function and electrical properties of the heart.
    Akkerman-Nijland AM; Möhlmann JE; Akkerman OW; Vd Vaart H; Majoor CJ; Rottier BL; Burgerhof JGM; Hak E; Koppelman GH; Touw DJ
    Expert Opin Drug Saf; 2021 Aug; 20(8):959-963. PubMed ID: 34030570
    [No Abstract]   [Full Text] [Related]  

  • 13. Azithromycin for improving pulmonary function in cystic fibrosis.
    Carr RR; Nahata MC
    Ann Pharmacother; 2004 Sep; 38(9):1520-4. PubMed ID: 15213312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of clinical trials in cystic fibrosis.
    Southern KW; Smyth RL
    Lancet; 2003 Jan; 361(9354):349-50; aurhor reply 350. PubMed ID: 12559892
    [No Abstract]   [Full Text] [Related]  

  • 15. Response to letter.
    Ratjen F; Anstead M; Lands L; Mayer-Hamblett N; Saiman L
    Pediatr Pulmonol; 2015 Jan; 50(1):105. PubMed ID: 24700677
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis.
    Wilms EB; Touw DJ; Heijerman HG
    Ther Drug Monit; 2006 Apr; 28(2):219-25. PubMed ID: 16628134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term azithromycin use is associated with QTc interval prolongation in children with cystic fibrosis.
    Enhoş A; Doğuş Kus H; Yozgat CY; Cakır E; Yazan H; Erol AB; Erenberk U; Yozgat Y
    Arch Pediatr; 2024 Jul; 31(5):315-319. PubMed ID: 38637249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steady-State Therapy with Azithromycin or Low-Dose Prednisolone in Paediatric Cystic Fibrosis Patients: Inflammatory Markers and Disease Progression.
    Shmarina G; Pukhalsky A; Avakian L; Semykin S; Pukhalskaya D; Alioshkin V
    Int Arch Allergy Immunol; 2017; 172(1):45-54. PubMed ID: 28219060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapidly progressive lung disease in a patient with cystic fibrosis on long-term azithromycin: possible role of mycoplasma infection.
    Janahi IA; Abdulwahab A; Elshafie Sittana S; Bush A
    J Cyst Fibros; 2005 Mar; 4(1):71-3. PubMed ID: 15752685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.
    Saiman L; Mayer-Hamblett N; Campbell P; Marshall BC;
    Am J Respir Crit Care Med; 2005 Oct; 172(8):1008-12. PubMed ID: 16040785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.